Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
Open Access
- 14 January 2021
- Vol. 10 (1), 152
- https://doi.org/10.3390/cells10010152
Abstract
NY-ESO-1-specific T cells have shown promising activity in the treatment of soft tissue sarcoma (STS). However, standardized protocols for their generation are limited. Particularly, cost-effectiveness considerations of cell production protocols are of importance for conducting clinical studies. In this study, two different NY-ESO-1-specific T cell production protocols were compared. Major differences between protocols 1 and 2 include culture medium, interleukin-2 and retronectin concentrations, T cell activation strategy, and the transduction process. NY-ESO-1-specific T cells generated according to the two protocols were investigated for differences in cell viability, transduction efficiency, T cell expansion, immunophenotype as well as functionality. NY-ESO-1-specific T cells showed similar viability and transduction efficiency between both protocols. Protocol 1 generated higher absolute numbers of NY-ESO-1-specific T cells. However, there was no difference in absolute numbers of NY-ESO-1-specific T cell subsets with less-differentiated phenotypes accounting for efficient in vivo expansion and engraftment. Furthermore, cells generated according to protocol 1 displayed higher capacity of TNF-α generation, but lower cytotoxic capacities. Overall, both protocols provided functional NY-ESO-1-specific T cells. However, compared to protocol 1, protocol 2 is advantageous in terms of cost-effectiveness. Cell production protocols should be designed diligently to achieve a cost-effective cellular product for further clinical evaluation.This publication has 41 references indexed in Scilit:
- Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic applicationCancer Letters, 2020
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1(c259) T Cells in Synovial SarcomaCancer Discovery, 2018
- NY-ESO-1 Based Immunotherapy of Cancer: Current PerspectivesFrontiers in Immunology, 2018
- Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapiesAdvanced Drug Delivery Reviews, 2017
- Immune targets and neoantigens for cancer immunotherapy and precision medicineCell Research, 2016
- Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic CancersJournal of Immunotherapy, 2016
- NY-ESO-1 (CTAG1B) expression in mesenchymal tumorsLaboratory Investigation, 2015
- The biology of cancer testis antigens: Putative function, regulation and therapeutic potentialMolecular Oncology, 2011
- Tumor Antigen Expression in Melanoma Varies According to Antigen and StageClinical Cancer Research, 2006
- NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesBlood, 2005